153 related articles for article (PubMed ID: 23993328)
1. Synthesis and biological evaluation of 2-amino-5-aryl-3-benzylthiopyridine scaffold based potent c-Met inhibitors.
Zhang D; Zhang X; Ai J; Zhai Y; Liang Z; Wang Y; Chen Y; Li C; Zhao F; Jiang H; Geng M; Luo C; Liu H
Bioorg Med Chem; 2013 Nov; 21(21):6804-20. PubMed ID: 23993328
[TBL] [Abstract][Full Text] [Related]
2. Discovery of 3H-imidazo[4,5-b]pyridines as potent c-Met kinase inhibitors: design, synthesis, and biological evaluation.
Chen D; Wang Y; Ma Y; Xiong B; Ai J; Chen Y; Geng M; Shen J
ChemMedChem; 2012 Jun; 7(6):1057-70. PubMed ID: 22581753
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and c-Met kinase inhibition of 3,5-disubstituted and 3,5,7-trisubstituted quinolines: identification of 3-(4-acetylpiperazin-1-yl)-5-(3-nitrobenzylamino)-7- (trifluoromethyl)quinoline as a novel anticancer agent.
Wang Y; Ai J; Wang Y; Chen Y; Wang L; Liu G; Geng M; Zhang A
J Med Chem; 2011 Apr; 54(7):2127-42. PubMed ID: 21405128
[TBL] [Abstract][Full Text] [Related]
4. Design and optimization of a series of 1-sulfonylpyrazolo[4,3-b]pyridines as selective c-Met inhibitors.
Ma Y; Sun G; Chen D; Peng X; Chen YL; Su Y; Ji Y; Liang J; Wang X; Chen L; Ding J; Xiong B; Ai J; Geng M; Shen J
J Med Chem; 2015 Mar; 58(5):2513-29. PubMed ID: 25668160
[TBL] [Abstract][Full Text] [Related]
5. Discovery and optimization of novel 4-phenoxy-6,7-disubstituted quinolines possessing semicarbazones as c-Met kinase inhibitors.
Qi B; Mi B; Zhai X; Xu Z; Zhang X; Tian Z; Gong P
Bioorg Med Chem; 2013 Sep; 21(17):5246-60. PubMed ID: 23838381
[TBL] [Abstract][Full Text] [Related]
6. MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor.
Pan BS; Chan GK; Chenard M; Chi A; Davis LJ; Deshmukh SV; Gibbs JB; Gil S; Hang G; Hatch H; Jewell JP; Kariv I; Katz JD; Kunii K; Lu W; Lutterbach BA; Paweletz CP; Qu X; Reilly JF; Szewczak AA; Zeng Q; Kohl NE; Dinsmore CJ
Cancer Res; 2010 Feb; 70(4):1524-33. PubMed ID: 20145145
[TBL] [Abstract][Full Text] [Related]
7. KRC-408, a novel c-Met inhibitor, suppresses cell proliferation and angiogenesis of gastric cancer.
Hong SW; Jung KH; Park BH; Zheng HM; Lee HS; Choi MJ; Yun JI; Kang NS; Lee J; Hong SS
Cancer Lett; 2013 May; 332(1):74-82. PubMed ID: 23348694
[TBL] [Abstract][Full Text] [Related]
8. Novel 6-aminofuro[3,2-c]pyridines as potent, orally efficacious inhibitors of cMET and RON kinases.
Steinig AG; Li AH; Wang J; Chen X; Dong H; Ferraro C; Jin M; Kadalbajoo M; Kleinberg A; Stolz KM; Tavares-Greco PA; Wang T; Albertella MR; Peng Y; Crew L; Kahler J; Kan J; Schulz R; Cooke A; Bittner M; Turton RW; Franklin M; Gokhale P; Landfair D; Mantis C; Workman J; Wild R; Pachter J; Epstein D; Mulvihill MJ
Bioorg Med Chem Lett; 2013 Aug; 23(15):4381-7. PubMed ID: 23773865
[TBL] [Abstract][Full Text] [Related]
9. Discovery of novel 2-aminopyridine-3-carboxamides as c-Met kinase inhibitors.
Zhang D; Ai J; Liang Z; Li C; Peng X; Ji Y; Jiang H; Geng M; Luo C; Liu H
Bioorg Med Chem; 2012 Sep; 20(17):5169-80. PubMed ID: 22863529
[TBL] [Abstract][Full Text] [Related]
10. Structure-based design, synthesis, and evaluation of imidazo[1,2-b]pyridazine and imidazo[1,2-a]pyridine derivatives as novel dual c-Met and VEGFR2 kinase inhibitors.
Matsumoto S; Miyamoto N; Hirayama T; Oki H; Okada K; Tawada M; Iwata H; Nakamura K; Yamasaki S; Miki H; Hori A; Imamura S
Bioorg Med Chem; 2013 Dec; 21(24):7686-98. PubMed ID: 24216091
[TBL] [Abstract][Full Text] [Related]
11. Discovery of a new series of imidazo[1,2-a]pyridine compounds as selective c-Met inhibitors.
Liu TC; Peng X; Ma YC; Ji YC; Chen DQ; Zheng MY; Zhao DM; Cheng MS; Geng MY; Shen JK; Ai J; Xiong B
Acta Pharmacol Sin; 2016 May; 37(5):698-707. PubMed ID: 27041462
[TBL] [Abstract][Full Text] [Related]
12. Discovery of potent 1H-imidazo[4,5-b]pyridine-based c-Met kinase inhibitors via mechanism-directed structural optimization.
An XD; Liu H; Xu ZL; Jin Y; Peng X; Yao YM; Geng M; Long YQ
Bioorg Med Chem Lett; 2015 Feb; 25(3):708-16. PubMed ID: 25529740
[TBL] [Abstract][Full Text] [Related]
13. Synthesis, and docking studies of phenylpyrimidine-carboxamide derivatives bearing 1H-pyrrolo[2,3-b]pyridine moiety as c-Met inhibitors.
Zhu W; Wang W; Xu S; Wang J; Tang Q; Wu C; Zhao Y; Zheng P
Bioorg Med Chem; 2016 Apr; 24(8):1749-56. PubMed ID: 26964675
[TBL] [Abstract][Full Text] [Related]
14. SOMG-833, a novel selective c-MET inhibitor, blocks c-MET-dependent neoplastic effects and exerts antitumor activity.
Zhang HT; Wang L; Ai J; Chen Y; He CX; Ji YC; Huang M; Yang JY; Zhang A; Ding J; Geng MY
J Pharmacol Exp Ther; 2014 Jul; 350(1):36-45. PubMed ID: 24741075
[TBL] [Abstract][Full Text] [Related]
15. Discovery of novel c-Met kinase inhibitors bearing a thieno[2,3-d]pyrimidine or furo[2,3-d]pyrimidine scaffold.
Zhao A; Gao X; Wang Y; Ai J; Wang Y; Chen Y; Geng M; Zhang A
Bioorg Med Chem; 2011 Jul; 19(13):3906-18. PubMed ID: 21665484
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and biological evaluation of novel 4-phenoxy-6,7-disubstituted quinolines possessing (thio)semicarbazones as c-Met kinase inhibitors.
Zhai X; Bao G; Wang L; Cheng M; Zhao M; Zhao S; Zhou H; Gong P
Bioorg Med Chem; 2016 Mar; 24(6):1331-45. PubMed ID: 26897090
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and structure-activity relationships of dual PI3K/mTOR inhibitors based on a 4-amino-6-methyl-1,3,5-triazine sulfonamide scaffold.
Wurz RP; Liu L; Yang K; Nishimura N; Bo Y; Pettus LH; Caenepeel S; Freeman DJ; McCarter JD; Mullady EL; Miguel TS; Wang L; Zhang N; Andrews KL; Whittington DA; Jiang J; Subramanian R; Hughes PE; Norman MH
Bioorg Med Chem Lett; 2012 Sep; 22(17):5714-20. PubMed ID: 22832322
[TBL] [Abstract][Full Text] [Related]
18. N3-arylmalonamides: a new series of thieno[3,2-b]pyridine based inhibitors of c-Met and VEGFR2 tyrosine kinases.
Saavedra O; Claridge S; Zhan L; Raeppel F; Granger MC; Raeppel S; Mannion M; Gaudette F; Zhou N; Isakovic L; Bernstein N; Déziel R; Nguyen H; Beaulieu N; Beaulieu C; Dupont I; Wang J; Macleod AR; Besterman JM; Vaisburg A
Bioorg Med Chem Lett; 2009 Dec; 19(24):6836-9. PubMed ID: 19896842
[TBL] [Abstract][Full Text] [Related]
19. EMD 1214063 and EMD 1204831 constitute a new class of potent and highly selective c-Met inhibitors.
Bladt F; Faden B; Friese-Hamim M; Knuehl C; Wilm C; Fittschen C; Grädler U; Meyring M; Dorsch D; Jaehrling F; Pehl U; Stieber F; Schadt O; Blaukat A
Clin Cancer Res; 2013 Jun; 19(11):2941-51. PubMed ID: 23553846
[TBL] [Abstract][Full Text] [Related]
20. Discovery and optimization of a potent and selective triazolopyridinone series of c-Met inhibitors.
Bode CM; Boezio AA; Albrecht BK; Bellon SF; Berry L; Broome MA; Choquette D; Dussault I; Lewis RT; Lin MH; Rex K; Whittington DA; Yang Y; Harmange JC
Bioorg Med Chem Lett; 2012 Jun; 22(12):4089-93. PubMed ID: 22595176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
